DeepMed Research

Loncastuximab

Generic Name: Loncastuximab

Clinical Trials

Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Phase 1

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Loncastuximab
Drug: Roflumilast
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2025-05-18

Last Posted Date: 2025-05-18

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 10

Registration Number: NCT06977711

Locations: 🇺🇸
University Hospital System, San Antonio, Texas, United States
🇺🇸
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy